	US 12,435,046 B2
	Alkynyl quinazoline compounds
Matthew C. Lucas, Lexington, MA (US); Fernando Padilla, Arlington, MA (US); Alexander Flohr, Basel (CH); Luca Arista, Riehen (CH); and Elizabeth Buck, Huntington, NY (US)
Assigned to Black Diamond Therapeutics, Inc., Cambridge, MA (US)
Appl. No. 17/635,578
Filed by Black Diamond Therapeutics, Inc., Cambridge, MA (US)
PCT Filed Aug. 14, 2020, PCT No. PCT/US2020/046425 § 371(c)(1), (2) Date Feb. 15, 2022, PCT Pub. No. WO2021/030711, PCT Pub. Date Feb. 18, 2021.
Claims priority of provisional application 63/065,028, filed on Aug. 13, 2020.
Claims priority of provisional application 62/887,392, filed on Aug. 15, 2019.
Prior Publication US 2022/0298120 A1, Sep. 22, 2022
Int. Cl. C07D 239/94 (2006.01); A61P 35/00 (2006.01); C07D 401/10 (2006.01); C07D 401/14 (2006.01); C07D 403/10 (2006.01); C07D 403/14 (2006.01); C07D 405/10 (2006.01); C07D 405/14 (2006.01); C07D 471/04 (2006.01); C07D 471/08 (2006.01); C07D 491/10 (2006.01); C07D 498/08 (2006.01)

CPC C07D 239/94 (2013.01) [A61P 35/00 (2018.01); C07D 401/10 (2013.01); C07D 401/14 (2013.01); C07D 403/10 (2013.01); C07D 403/14 (2013.01); C07D 405/10 (2013.01); C07D 405/14 (2013.01); C07D 471/04 (2013.01); C07D 471/08 (2013.01); C07D 491/10 (2013.01); C07D 498/08 (2013.01)]

20 Claims

1. A compound selected from:


Com-
pound
No.	Structure

1

2

3

4

5

6

7

8

10

11

12

13

14

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

37A

37B

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

and pharmaceutically acceptable salts thereof.